Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Benign Prostatic Hyperplasia Present at screening with a history of benign prostatic hyperplasia (BPH) for >6 months Have an International Prostate Symptom Score (IPSS) greater than or equal to 13 at screening Have a total prostate volume by transrectal ultrasound greater than or equal to 30 milliliter (mL) at screening Show signs of bladder outlet obstruction as defined by a peak urinary flow rate (Qmax) greater than or equal to 4 and less than or equal to 15 milliliter/second (mL/sec) (from a prevoid total bladder volume [assessed by ultrasound] of greater than or equal to 150 to less than or equal to 550 ml and a minimum voided volume of 125 ml) at screening Have a prostate-specific antigen (PSA) greater than or equal to 1.4 and less than or equal to 10 nanogram/milliliter (ng/mL) at screening Demonstrate a Post Void Residual less than or equal to 300 mL by ultrasound at screening Have not received the following treatments within the specified time period: 1. Finasteride or dutasteride for at least 6 months prior to screening. 2. Any alpha-adrenergic antagonists for at least 4 weeks prior to screening. 3. Any other non-experimental BPH therapy (including an herbal preparation) for at least 4 weeks prior to screening. 4. Any other experimental or off-label BPH therapy such as injectable therapies with a protracted effect for at least 6 months prior to screening. 5. Any overactive bladder treatment for at least 4 weeks prior to screening. 6. Any Erectile Dysfunction treatment which may oral phosphodiesterase type 5 inhibitors or devices for at least 4 weeks prior to screening Have a morning fasting Total Testosterone concentration greater than or equal to 300 nanogram/deciliter (ng/dL) at screening If hyperlipidemic, based on history, be stable on statin treatment as determined by the investigator for at least 2 months prior to screening  Have completed or withdrawn from this study or have completed or withdrawn from any other study investigating LY500307 Have any history of BPH-related invasive procedures (for example, Transurethral Resection of the Prostate, open prostatectomy, and minimally invasive procedures that thermal-based therapies, transurethral microwave treatment, transurethral needle ablation, and stents) Have active cardiovascular disease as evidenced by the following: 1. Recent Myocardial infarction, unstable angina, stroke or Transient ischemic attack within 6 months of screening. 2. Recent coronary intervention that includes coronary artery bypass surgery, percutaneous coronary artery intervention, or stent placement within 6 months of screening. 3. Recent history of positive stress tests without any written documentation of effective intervention within 6 months of screening. 4. Evidence of heart disease categorized as greater than or equal to Class III functional classification of New York Heart Association (NYHA) within 6 months of screening Have known or suspected history of prostate cancer, breast cancer, or other clinically significant neoplastic disease (other than squamous cell or basal cell carcinoma of skin) Have a history of deep venous thrombosis or pulmonary embolism disease Have moderate to severe renal insufficiency Have a hemoglobin A1c (HbA1c) greater than 9.0% Are on testosterone replacement therapy, or drugs that influence the hypothalamus-pituitary-gonadal axis Are on pharmacological treatment other than statins for hyperlipidemia